EP1147777A1 — Combination of defibrotide and G-CSF and its use to activate haematopoietic progenitors
Assigned to Crinos Industria Farmacobiologica SpA · Expires 2001-10-24 · 25y expired
What this patent protects
A description is given of a method of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the method is characterised by the administration of defibrotide in combination or in temporal proximity with at least one haematopoi…
USPTO Abstract
A description is given of a method of increasing the amount of stem cells and progenitor cells in circulation in the peripheral blood of a mammal; the method is characterised by the administration of defibrotide in combination or in temporal proximity with at least one haematopoietic factor having the capacity to mobilise haematopoietic progenitors, preferably G-CSF.
Drugs covered by this patent
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.